Kyla Driscoll

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

Rikke Holmgaard, David Schaer, Yanxia Li et al. · Journal for ImmunoTherapy of Cancer · 2018 · 358 citations · Full text

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor

Jonathan M. Yingling, William T. McMillen, Lei Yan et al. · Oncotarget · 2017 · 168 citations · Full text

A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors

Anthony W. Tolcher, Jordan Berlin, Jan Cosaert et al. · Cancer Chemotherapy and Pharmacology · 2017 · 99 citations · Full text

Lymphoid Neoplasia, Medicine, Immunology +8

TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer

Davide Melisi, Rocio García‐Carbonero, Teresa Macarulla et al. · Cancer Chemotherapy and Pharmacology · 2019 · 90 citations

Tumor Biology, Pancreatic Cancer, Immunology +5

Autocrine TGFβ Is a Survival Factor for Monocytes and Drives Immunosuppressive Lineage Commitment

Alba Gonzàlez-Juncà, Kyla Driscoll, Ilenia Pellicciotta et al. · Cancer Immunology Research · 2018 · 82 citations · Full text